Navigation Links
JDRF Applauds Launch of New Low Glucose Suspend Technology
Date:9/27/2013

WASHINGTON, Sept. 27, 2013 /PRNewswire-USNewswire/ -- JDRF, the leading global organization funding type 1 diabetes (T1D) research, today applauded the U.S. Food and Drug Administration (FDA) for its commitment to ensuring patients in the United States can access insulin pumps that can temporarily stop insulin delivery once sensor glucose levels fall below a predetermined threshold. This morning, Medtronic announced FDA approval of its MiniMed 530G with Enlite system (sold outside the United States as the Veo since 2009). 

"This approval means people with type 1 diabetes will have access to technologies on par with the rest of the world," said Jeffrey Brewer, president and CEO of JDRF. "We appreciate all that the FDA and Medtronic have done to bring this system to people with type 1 diabetes in the U.S., and look forward to working with researchers, regulators, and the private sector to accelerate the delivery of even more impactful improvements in technology to more effectively manage the disease."

JDRF continues to work with Medtronic and other industry and academic partners on a series of advances that will one day lead to a fully automated, closed-loop system that can truly be called an artificial pancreas. On the way to that goal, approaches to preventing hypoglycemia and implementing fully closed-loop control overnight have been demonstrated to work in outpatient clinical trials funded by JDRF and the National Institutes of Health (NIH). JDRF is committed to continuing its efforts well beyond this meaningful first step in automation by working with the FDA and medical device companies to accelerate these life-improving, and in some cases lifesaving, technologies for people with T1D. 

About JDRF

JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.

As the largest charitable supporter of T1D research, JDRF is currently sponsoring $530 million in scientific research in 17 countries. In 2012 alone, JDRF provided more than $110 million to T1D research. More than 80 percent of JDRF's expenditures directly support research and research-related education. In 2012 Forbes magazine named JDRF one of its five All-Star charities, citing the organization's efficiency and effectiveness.

For more information, please visit jdrf.org.


'/>"/>
SOURCE JDRF
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CHPA Applauds Alabama Senates Passage of Anti-Meth Bill
2. CHPA Applauds Alabamas Adoption Of HB 363
3. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
4. CHPA Applauds Arizonas Adoption Of HB 2263
5. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
6. Obesity Care Continuum (OCC) Applauds FDA for Approval of New Obesity Drug
7. Novation Applauds FDAs Unique Device Identification Rule
8. American Academy of Pain Medicine Applauds FDA Action to Enhance Patient Safety on Prescribing Opioids; Offers AAPM Safe Opioid Prescribing Course as Educational Model
9. Mylan Applauds Signing of Landmark "Food and Drug Administration Safety and Innovation Act"
10. ADVENTRX Applauds Inclusion of Rare Diseases Provisions in the FDA Safety and Innovation Act
11. CRN Applauds Introduction Of Designer Anabolic Steroid Control Act
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
(Date:12/2/2016)... 2, 2016 bioLytical Laboratories, ein Weltführer bei schnellen ... Mitgliedern des Apothekenbundes von Kenia eingeführt. Continue ... ... HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical wurde ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, ... Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 ... details line up exactly with Bible Prophecy – a protected way for those who ...
(Date:12/2/2016)... ... 02, 2016 , ... On November 24th, 2016, Thanksgiving morning, ... different sites throughout Miami-Dade and Broward counties. This is the largest meal delivery ... Thanksgiving morning by putting together individual meals via assembly lines and passing them ...
(Date:12/2/2016)... ... December 02, 2016 , ... ‘Tis the season for giving! Today, 20 ... the National Family Partnership and the Drug Enforcement Administration as part of the National ... the 10 winning schools who decorated their campuses with this year’s Red Ribbon Week ...
Breaking Medicine News(10 mins):